Scout | FY26 ALS Research Program Therapeutic Development Award for preclinical-to-IND drug studies

nofo

FY26 ALS Research Program Therapeutic Development Award for preclinical-to-IND drug studies

This award funds mechanism-driven ALS therapeutic development, from preclinical validation of leads through FDA IND-enabling work. Projects must start with lead compounds in hand and already show proof-of-concept efficacy in relevant ALS whole-animal and cellular models. A key requirement is parallel development of mechanism-specific, predictive biomarkers for target engagement and pharmacodyn…

Source

Agency: Dept. of the Army -- USAMRAA

Award

Total Funding: $12M

Dates

Open Date: May 4, 2026

Close Date: September 30, 2026

Eligibility

industry:research

Keywords

als therapeutics

preclinical validation

ind-enabling studies

biomarker development

target engagement

pharmacodynamics

amyotrophic lateral sclerosis

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers